Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: LLY stock price vs AMGN: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at AMGN's multiple
Needs AMGN P/E.
Implied fair value · at LLY's multiple
Needs LLY P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
ELI LILLY AND COMPANY · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Amgen Inc. · implied price per share
Bear
$98.66
Base
$130.87
Bull
$172.82
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Pfizer Inc.
LLY vs PFE
Merck & Co., Inc.
LLY vs MRK
Johnson & Johnson
LLY vs JNJ
AbbVie Inc.
LLY vs ABBV
Bristol-Myers Squibb Company
LLY vs BMY
REGENERON PHARMACEUTICALS, INC.
LLY vs REGN
BIOGEN INC.
LLY vs BIIB
VERTEX PHARMACEUTICALS INC / MA
LLY vs VRTX
Gilead Sciences, Inc.
LLY vs GILD
Moderna, Inc.
LLY vs MRNA
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe LLY can sustain its 44.7% revenue growth and premium margin profile, then hold or accumulate on weakness because the operating fundamentals justify a higher multiple even though the current price is well above AMGN-implied and DCF ranges.
LLY trades at a large premium to AMGN on every valuation multiple provided, which is consistent with its much stronger growth and profitability profile. However, the current price of $1148.84 sits above AMGN-implied range and far above the DCF range, while remaining within the historical band.
Supporting Metrics
